Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Jason Donville is president and CEO of Donville Kent Asset Management. His focus is growth stocks.

Top Picks:

Concordia Healthcare (CXR.TO)

Story continues below advertisement

Concordia is an international pharma company that trades at 4.0x 2016 earnings and below its projected year-end book value. Concordia has not been plagued by pricing or accounting issues, but it is highly levered and this explains its discount valuation. However, as the company moves through 2016 and pays down its debt, we think Concordia will re-rate significantly.

MTY Food Group (MTY.TO)

Montreal-based MTY has consistently earned an ROE in excess of 20 per cent over the past decade. MTY operates a number of fast food restaurant chains in Canada, and with the stock having been in consolidation mode for the past year and a half, now trades on 12.5x 2016 earnings, which we think is very reasonable for a steady growth company with an unlevered balance sheet.

CGI Group (GIBa.TO)

CGI Group is a Montreal-based IT services company with a global reach. CGI is a consistent 20-per-cent grower and a superb allocator of capital. The company is in the midst of buying back a large block of stock from the CDP, which will ensure another year of strong EPS growth and above market ROE. CGI trades on 12.8x 2016 earnings.

Past Picks: February 5, 2015

Valeant Pharmaceuticals (VRX.TO)

Story continues below advertisement

New comments: Sold most of our position at the end of November 2015. Current weighting is 0.5 per cent.

Then: $200.43 Now: $87.15 -56.52% Total return: -56.52%

Constellation Software (CSU.TO)

New comments: Our second largest position, with a 11.6-per-cent weighting.

Then: $376.15 Now: $527.72 +40.30% Total return: +41.69%

CGI Group (GIBa.TO)

Story continues below advertisement

New comments: Our largest position, with a 12-per-cent weighting.

Then: $50.88 Now: $56.40 +10.85% Total return: +10.85%

Total Return Average: -1.33%

Market outlook:

The TSX last peaked in the Autumn of 2014 and has been in correction mode ever since. The Canadian market has been weaker than most other countries because of its high weighting in natural resource stocks and the effect the price of oil has had on the Canadian dollar. As such, while the TSX has rebounded nicely over the past month, we still consider it to be an oversold market.

Looking ahead, it is hard to see economic growth anywhere in the world given low demographic growth in virtually all western countries and many emerging markets. However, pockets of growth exist everywhere, including Canada. Health care stands out as a sector that offers compelling growth and valuation opportunities and the technology, consumer and financial sectors also offer some bargains.

Story continues below advertisement

For investors in Canadian equities, the past six months have been particularly volatile and remind us that trying to rapidly trade stocks through a volatile market is both stressful and costly. Investors should focus on companies that have enduring competitive advantages and be prepared to hold these stocks through choppy waters. High ROE stocks, which is our area of focus, offer both growth and a certain measure of protection that comes from their competitive positions and is reflected in their margins.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies